Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Targeted Treatment of Oral Cancer
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Targeted Treatment of Oral Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dentistry, Oral Surgery and Oral Medicine".

Deadline for manuscript submissions: 20 December 2025 | Viewed by 1277

Special Issue Editors

Dr. Yasmine Ghantous

E-Mail Website
Guest Editor
Department of Oral and Maxillofacial Surgery, Baruch Padeh Medical Center Poriya, Tiberias 158001, Israel
Interests: oral and maxillofacial surgery; facial aesthetic surgery; basic science; head and neck cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Claudia Malheiros Coutinho-Camillo

E-Mail
Guest Editor
International Research Center, A. C. Camargo Cancer Center, Rua Taguá 440, São Paulo 01508-010, Brazil
Interests: genetics; molecular biology

Special Issue Information

Dear Colleagues,

Oral cancer is a significant global health concern, with increasing incidence rates and diverse treatment approaches. The Special Issue focuses on targeted treatment strategies that aim to improve therapeutic outcomes while minimizing adverse effects. By exploring personalized medicine approaches and innovative therapeutic modalities, this Special Issue aims to contribute to the advancement of clinical practice in oral cancer treatment.

The Special Issue invites original research articles and reviews that cover a wide range of topics related to the targeted treatment of oral cancer. We encourage submissions that address the following areas:

  1. Novel therapeutic agents and drug delivery systems;
  2. Immunotherapy and its role in oral cancer treatment;
  3. Combination therapies and their synergistic effects.

We hope that this collection of articles will facilitate the development of more effective and personalized treatment strategies, ultimately improving patient outcomes in the field of oral oncology.

Dr. Yasmine Ghantous
Dr. Claudia Malheiros Coutinho-Camillo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision medicine
  • immunotherapy
  • targeted drugs
  • combination therapy
  • tumor immune evasion
  • clinical trials

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 700 KiB  
Article
MicroRNA Profiles Distinguishing Metastatic from Non-Metastatic Salivary Mucoepidermoid Carcinoma
by Maria Eduarda Salles Trevizani, Fabio Albuquerque Marchi, Daniela Bizinelli, Katia Klug Oliveira, Fernanda Viviane Mariano, Cibele Pidorodeski Nagano, Felipe D’Almeida Costa, Clóvis Antonio Lopes Pinto, Luiz Paulo Kowalski, Silvia Vanessa Lourenço and Cláudia Malheiros Coutinho-Camillo
J. Clin. Med. 2025, 14(14), 4957; https://doi.org/10.3390/jcm14144957 (registering DOI) - 13 Jul 2025
Abstract
Background/Objectives: Mucoepidermoid carcinoma (MEC) is the most common malignant tumor of the salivary glands. Metastatic spread occurs in up to 80% of high-grade tumors; however, the mechanisms underlying this process are largely unknown. Large-scale microRNA (miRNA) expression profiling studies of human cancers have [...] Read more.
Background/Objectives: Mucoepidermoid carcinoma (MEC) is the most common malignant tumor of the salivary glands. Metastatic spread occurs in up to 80% of high-grade tumors; however, the mechanisms underlying this process are largely unknown. Large-scale microRNA (miRNA) expression profiling studies of human cancers have demonstrated that dysregulation of miRNA is frequently associated with many cancer types. This study aimed to investigate the miRNA profiles of metastatic and non-metastatic MECs. Methods: Using real-time RT-PCR (qPCR), we analyzed the expression of 377 miRNAs in four non-metastatic MECs, three MECs with lymph node metastasis, three MECs with distant metastasis, and two non-neoplastic human salivary glands. To identify differentially expressed miRNAs, bioinformatics analysis was performed using hierarchical clustering analysis. Results: The miRNA profile discriminated between non-neoplastic and tumor samples and between metastatic and non-metastatic tumors. Twelve miRNAs were differentially expressed between non-neoplastic and non-metastatic MECs. MEC analysis of non-neoplastic and lymph node metastases demonstrated that 10 miRNAs were differentially expressed. In non-neoplastic versus distant metastatic MECs, three miRNAs were differentially expressed: one downregulated and two upregulated. By comparing non-metastatic MECs with lymph node metastatic MECs, we identified 17 upregulated miRNAs. Considering non-metastatic MECs versus distant metastatic MECs, two miRNAs were upregulated. One miRNA was differentially expressed between lymph node metastatic and distant metastatic MECs. Conclusions: Our findings indicated that miRNA profiles may serve as valuable biomarkers for distinguishing the metastatic potential of salivary MECs, warranting further investigation to validate their utility in clinical practice. Full article
(This article belongs to the Special Issue Targeted Treatment of Oral Cancer)
►▼ Show Figures

Figure 1

10 pages, 2716 KiB  
Article
Gold-Nanoparticles Reflectance Discriminates Benign from Malignant Salivary Gland Neoplasms
by Shiran Sudri, Irit Allon, Ilana Kaplan, Abraham Hirshberg, Dror Fixler and Imad Abu El-Naaj
J. Clin. Med. 2025, 14(5), 1672; https://doi.org/10.3390/jcm14051672 - 1 Mar 2025
Viewed by 980
Abstract
Objectives: This study aimed to assess the effectiveness of gold nanoparticles conjugated with anti-EGFR monoclonal antibodies (GNPs-EGFR) in distinguishing between benign and malignant salivary gland tumors. Methods: A total of 49 oral salivary gland tissue samples were analyzed, including 22 malignant salivary gland [...] Read more.
Objectives: This study aimed to assess the effectiveness of gold nanoparticles conjugated with anti-EGFR monoclonal antibodies (GNPs-EGFR) in distinguishing between benign and malignant salivary gland tumors. Methods: A total of 49 oral salivary gland tissue samples were analyzed, including 22 malignant salivary gland tumors (MSGTs), 15 benign salivary gland tumors (BSGTs), and 12 control samples. For each sample, three 5 μm consecutive tissue sections were prepared. The first section was stained with hematoxylin and eosin (H&E) to confirm the diagnosis, the second was immunohistochemically stained for anti-EGFR, and the third was treated with GNPs-EGFR followed by hyperspectral microscopy to analyze the reflectance spectrum. Results: Reflectance intensity was significantly higher (p < 0.001) in MSGTs compared to BSGTs and controls, with intensity levels increasing alongside tumor grade. The average hyperspectral reflectance values were strongly correlated with the GNPs-EGFR immunohistochemical score and varied significantly between subgroups (p < 0.001). Conclusions: GNPs-EGFR reflection measurements effectively differentiate MSGTs from BSGTs with high sensitivity. This diffusion–reflection technique holds potential as a valuable tool for tumor detection, surgical margin assessment, and intraoperative identification of residual disease in salivary gland tumors. Full article
(This article belongs to the Special Issue Targeted Treatment of Oral Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop